Skip to main content
. 2022 Jan 19;10(1):e003488. doi: 10.1136/jitc-2021-003488

Figure 7.

Figure 7

Intratumoral VVGM-αCTLA-4 synergizes with αPD-1 to reject ‘cold’ immune checkpoint blockade-resistant tumors. (A, B) C57BL/6 mice carrying two B16 tumors, one large (5×105 cells, treated tumor) and one small tumor (1×105 cells, contralateral side) received three intratumoral injections with VVGM-αCTLA-4 (vertical dotted lines) and/or intraperitoneal αPD-1 (29F.1A12, 10 mg/kg; two times per week for 3 weeks, gray area). (A) Survival (n=10–20), *p<0.05 by log-rank test. (B) Tumor growth curves of intratumorally injected and contralateral tumors. (C) A20 tumor-bearing BALB/c mice were treated thrice with VVGM-αCTLA-4 intratumorally (at a suboptimal dose of 1×105 pfu), αPD-1 intraperitoneally (RMP1-14, full dose of 10 mg/kg) or the combination of both when tumors had reached a volume of ~135 mm3. Graph shows animal survival (n=10). VV, vaccinia virus.